Who is sponsoring NCT03762018?

NCT03762018 is sponsored by ETOP IBCSG Partners Foundation.

What drugs are being tested in NCT03762018?

Interventions in NCT03762018: Carboplatin, Pemetrexed, Bevacizumab, Atezolizumab.

What condition does NCT03762018 study?

NCT03762018 studies Pleural Mesothelioma Malignant Advanced.

Is NCT03762018 still recruiting?

NCT03762018 is currently completed. Last updated 4 June 2025.

Last reviewed 2025-06-04 · How we verify

NCT03762018: BEAT-meso

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma

Completed Phase 3 Last updated 4 June 2025

What this trial tests

Phase 3 trial testing Carboplatin in Pleural Mesothelioma Malignant Advanced in 401 participants. Completed in 18 November 2024.

Timeline

30 April 2019

Primary endpoint
1 September 2023

18 November 2024

Quick facts

Lead sponsor	ETOP IBCSG Partners Foundation
Phase	Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	401
Start date	30 April 2019
Primary completion	1 September 2023
Estimated completion	18 November 2024
Sites	42 locations across France, Italy, Belgium, United Kingdom, Switzerland, Spain

Drugs / interventions tested

Carboplatin (Carboplatin) — full drug profile →
Pemetrexed — full drug profile →
Bevacizumab (Bevacizumab-Bvzr) — full drug profile →
Atezolizumab (atezolizumab) — full drug profile →

Conditions studied

Pleural Mesothelioma Malignant Advanced — all drugs for Pleural Mesothelioma Malignant Advanced →

Sponsor

ETOP IBCSG Partners Foundation

Who can join

18 and older, any sex, with Pleural Mesothelioma Malignant Advanced. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this clinical trial is to assess the effect of treatment with a monoclonal antibody called atezolizumab in patients diagnosed with a type of lung cancer called malignant pleural mesothelioma. The efficacy (whether the treatment works), safety and tolerability (side effects of treatment) of atezolizumab plus bevacizumab in combination with standard chemotherapy versus bevacizumab in combination with standard chemotherapy will be investigated.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting Tumor Microenvironment for Cancer Therapy.
Roma-Rodrigues C, Mendes R, Baptista PV, Fernandes AR. · · 2019 · cited 865× · PMID 30781344 · DOI 10.3390/ijms20040840
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities.
Hack SP, Zhu AX, Wang Y. · · 2020 · cited 223× · PMID 33250900 · DOI 10.3389/fimmu.2020.598877
Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ, Chen JX, Sun ZJ. · · 2021 · cited 63× · PMID 34137513 · DOI 10.1002/cac2.12183
New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options.
Tsao AS, Pass HI, Rimner A, Mansfield AS. · · 2022 · cited 56× · PMID 34985934 · DOI 10.1200/jco.21.01567
Immunotherapy in Malignant Pleural Mesothelioma.
de Gooijer CJ, Borm FJ, Scherpereel A, Baas P. · · 2020 · cited 54× · PMID 32154179 · DOI 10.3389/fonc.2020.00187
Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?
Cantini L, Hassan R, Sterman DH, Sterman DH, et al · · 2020 · cited 47× · PMID 32226777 · DOI 10.3389/fonc.2020.00343
Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives.
Gray SG, Mutti L. · · 2020 · cited 47× · PMID 32206576 · DOI 10.21037/tlcr.2019.11.23
Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism.
Yang F, Lee G, Fan Y. · · 2024 · cited 45× · PMID 38580870 · DOI 10.1007/s10456-024-09913-z

Verify or expand the search:

Other trials of Carboplatin

Trials testing the same drug.

NCT04832438 — 9-ING-41 Plus Carboplatin in Patients With Advanced, Metastatic Salivary Gland Carcinoma · Phase 2 · withdrawn
NCT07229339 — Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer · Phase 2 · not yet recruiting
NCT07346196 — A Trial of Locoregionally Advanced Squamous Cell Carcinoma of The Head and Neck · Phase 2 · not yet recruiting
NCT07441681 — Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive · Phase 3 · not yet recruiting
NCT07281417 — Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasa · Phase 2 · recruiting

Other ETOP IBCSG Partners Foundation trials

Trials by the same sponsor.

NCT05718297 — Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer · Phase 2 · withdrawn
NCT05896566 — A Window-of-Opportunity Trial of Giredestrant +/- Triptorelin vs. Anastrozole + Triptorelin in Premenopausal Patients Wi · Phase 2 · completed
NCT05601973 — Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progressio · Phase 2 · active not recruiting
NCT04908956 — Osimertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR Mutant NSCLC (STEREO) · Phase 2 · terminated
NCT04245085 — ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03762018 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ETOP IBCSG Partners Foundation
Last refreshed: 4 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03762018.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing